Rigel Pharmaceuticals
RIGL
169 hedge funds and large institutions have $426M invested in Rigel Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 10 closing their positions.
440% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 10
64% more capital invested
Capital invested by funds: $260M → $426M (+$165M)
35% more funds holding
Funds holding: 125 → 169 (+44)
29% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $1.9M
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
6.03% more ownership
Funds ownership: 77.72% → 83.75% (+6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$16.6M |
| 2 |
D.E. Shaw & Co
New York
|
+$9.17M |
| 3 |
Jane Street
New York
|
+$9.11M |
| 4 |
Renaissance Technologies
New York
|
+$7.11M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$41.1M |
| 2 |
AC
Armistice Capital
New York
|
-$26.2M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$9.82M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.6M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.93M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
US Bancorp
Minneapolis,
Minnesota
| – | -$87.6K | -4,677 | Closed |
|
|
RWM
177
RMG Wealth Management
Platteville,
Wisconsin
| – | -$41.5K | -2,205 | Closed |
|
|
CA
178
Clearstead Advisors
Cleveland,
Ohio
| – | -$1.09K | -58 | Closed |
|
|
RIL
179
Rothschild Investment LLC
Chicago,
Illinois
| – | -$187 | -10 | Closed |
|
RIGL Hedge Fund Activity: Q3 2025 in Review
169 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2025, worth a combined $426M — up 64% from $260M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new RIGL positions and 10 closed out — a net gain of 44 holders — while 52 added to existing stakes and 46 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $16.6M. The largest seller was Morgan Stanley, cutting an estimated $41.1M.
- 169 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2025, up from 125 in Q2 2025.
- Funds reported $426M of Rigel Pharmaceuticals stock for Q3 2025, up 64% quarter-over-quarter.
- 54 funds opened new Rigel Pharmaceuticals positions in Q3 2025 and 10 closed out, a net change of +44 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2025 was Goldman Sachs, an estimated $16.6M added.
- The largest Rigel Pharmaceuticals seller in Q3 2025 was Morgan Stanley, an estimated $41.1M sold.
Based on aggregated 13F filings for Q3 2025.